iShares Biotechnology ETF (IBB)
From Laggard to Leader: The Surprising Comeback of Healthcare
Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.
Biotech's Silent Resurgence (5-Year Base Breakout)
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
Should You Invest in the iShares Biotechnology ETF (IBB)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on February 5, 2001.
IBB: Space Stocks And AI Stealing The Risk-On Show In 2026
I reiterate a Hold rating on the iShares Nasdaq Biotechnology ETF, citing modest valuation but lackluster momentum and unfavorable market themes. IBB lags the S&P 500 YTD and faces headwinds as speculative capital favors AI and space stocks over biotech. The ETF's technical setup is mixed, with key resistance at $170 and potential upside to $190 if a breakout occurs.
Biotech Investors Are Tuning Out the MAHA Chaos
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead
The bulk of coverage towards the top gaining stock sectors over the past year has focused understandably on technology, which has made huge strides, with semiconductors exceeding +60%.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.
